close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ARS Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
News headline image
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY SPRY
News headline image
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SPRY
News headline image
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SBTX SPRY
News headline image
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SBTX SPRY
News headline image
ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SBTX SPRY
News headline image
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SBTX SPRY
News headline image
ARS Pharmaceuticals Announces FDA Acceptance of NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.